

Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? *Blood*. 2022;139(18):2737-2746.

Page 2739: In Figure 1, in the rightmost column of the “Pivotal trial” row, the clinical trial “Transform” should read “Transcend.” The corrected Figure 1 is shown below.

	Axi-cel	Tisa-cel	Liso-cel
CD19 scFv	FMC63	FMC63	FMC63
Signal 2	CD28	41BB	41BB
Signal 1	CD3ξ	CD3ξ	CD3ξ
Source	Fresh unsorted PBMCs	Cryopreserved unsorted PMBCs	Fresh sorted PBMCs
Viral vector	Gamma retrovirus	Lentivirus	Lentivirus
Pivotal trial	ZUMA-1	Juliet	Transcend
Most mature follow up (m)	63.1	40.3	24
Median duration of response (m)	11.1	NE	23.1
ORR/CR (%)	83/58	52/39	73/53
Median PFS (m)	5.9	2.9	6.8
PFS, 24 m (%)	36	33*	40.6
Median OS (m)	25.8	11.1	27.3
OS, 24 m (%)	50.5	40*	50.5
CRS: Any/Gr3+ (%)	93/13	57/23	42/2
Neuro tox: Any/Gr3+ (%)	64/28	20/11	30/10

Figure 1. Distinguishing features of the US Food and Drug Administration–approved CAR T-cell constructs and updated outcomes from the pivotal trials.^{25,26,28,36}

<https://doi.org/10.1182/blood.2022018793>

© 2023 by The American Society of Hematology

Downloaded from http://ashpublications.net/blood/article-pdf/141/6/683/2032807/blood_bld-2022-018793-main.pdf by guest on 08 June 2024